Jaguar HealthJAGX
Market Cap: $10.3M
About: Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Employees: 49
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
7.5% less ownership
Funds ownership: 9.59% [Q1] → 2.1% (-7.5%) [Q2]
30% less capital invested
Capital invested by funds: $524K [Q1] → $367K (-$157K) [Q2]
40% less funds holding
Funds holding: 20 [Q1] → 12 (-8) [Q2]
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 8
Research analyst outlook
We haven’t received any recent analyst ratings for JAGX.
Financial journalist opinion
Based on 6 articles about JAGX published over the past 30 days